Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 6/20 | 0.55 |
| ▸ | JAK3 | P52333 | 4/20 | 0.47 |
| ▸ | ABL1 | P00519 | 6/20 | 0.46 |
| ▸ | KIT | P10721 | 6/20 | 0.46 |
| ▸ | BCR | P11274 | 4/20 | 0.46 |
| ▸ | ABL2 | P42684 | 3/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | DDX3X | O00571 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247806 | 0.93 | JAK2 (0.55) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3247393 | 0.89 | JAK2 (0.59) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3252610 | 0.84 | JAK2 (0.53) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3251036 | 0.83 | JAK2 (0.53) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3256351 | 0.83 | JAK2 (0.54) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3255240 | 0.82 | JAK2 (0.59) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3247584 | 0.79 | JAK2 (0.58) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3258055 | 0.79 | JAK2 (0.60) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3254769 | 0.77 | JAK2 (0.53) | JAK2JAK3ABL1KITBCR | |
| SCHEMBL3250061 | 0.76 | JAK2 (0.54) | JAK2JAK3ABL1KITBCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | FURET PASCAL | 2006-05-18 | — | — | US | claimed |
| US-7691855-B2 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yl)-amine derivatives | NOVARTIS AG (CH) | 2010-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106027-A1 | Phenyl-[4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yI)-amine derivatives | MKI67, CCNI, PAH | JAK2 24/4885JAK3 41/4885ABL1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.